193357-52-7 Usage
Uses
Used in Pharmaceutical Industry:
4-(4-FLUOROBENZYL)PIPERIDINE HYDROCHLORIDE is used as a reactant for the synthesis of 4-(Substituted-benzyl)piperidines and (±)-3-(Substituted-benzyl)pyrrolidines. It plays a vital role in the creation of pharmaceutical compounds with potential applications in treating various medical conditions.
As a pharmaceutical intermediate, 4-(4-FLUOROBENZYL)PIPERIDINE HYDROCHLORIDE is instrumental in the development of new drugs and the enhancement of existing ones. Its ability to be modified and incorporated into different chemical structures allows for the exploration of novel therapeutic agents with improved efficacy and safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 193357-52-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,3,3,5 and 7 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 193357-52:
(8*1)+(7*9)+(6*3)+(5*3)+(4*5)+(3*7)+(2*5)+(1*2)=157
157 % 10 = 7
So 193357-52-7 is a valid CAS Registry Number.
InChI:InChI=1/C12H16FN.ClH/c13-12-3-1-10(2-4-12)9-11-5-7-14-8-6-11;/h1-4,11,14H,5-9H2;1H
193357-52-7Relevant academic research and scientific papers
4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists
-
, (2011/05/18)
PCT No. PCT/US96/20872 Sec. 371 Date Sep. 16, 1998 Sec. 102(e) Date Sep. 16, 1998 PCT Filed Dec. 20, 1996 PCT Pub. No. WO97/23216 PCT Pub. Date Jul. 3, 1997Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 4-substituted piperidine analogs are selective active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, psychosis, anxiety, migraine headaches, glaucoma, CMV retinitis, aminoglycoside antibiotics-induced hearing loss, convulsions, chronic pain, opioid tolerance or withdrawal, urinary incontinence or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.
